WO2024093156A1 - 一种头孢他啶连续制备方法 - Google Patents

一种头孢他啶连续制备方法 Download PDF

Info

Publication number
WO2024093156A1
WO2024093156A1 PCT/CN2023/089405 CN2023089405W WO2024093156A1 WO 2024093156 A1 WO2024093156 A1 WO 2024093156A1 CN 2023089405 W CN2023089405 W CN 2023089405W WO 2024093156 A1 WO2024093156 A1 WO 2024093156A1
Authority
WO
WIPO (PCT)
Prior art keywords
ceftazidime
solution
crystallizer
stirring
dihydrochloride
Prior art date
Application number
PCT/CN2023/089405
Other languages
English (en)
French (fr)
Inventor
杨梦德
王利杰
李贺
王克华
张民
刘荣亮
柳国宁
吕动晨
刘新彦
段哲昂
刘萍
马亚松
谷海泽
程浩
郭雄伟
Original Assignee
华北制药河北华民药业有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 华北制药河北华民药业有限责任公司 filed Critical 华北制药河北华民药业有限责任公司
Publication of WO2024093156A1 publication Critical patent/WO2024093156A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/02—Preparation
    • C07D501/12—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to a continuous preparation method of ceftazidime, belonging to the technical field of medicines.
  • Ceftazidime is a third-generation cephalosporin antibiotic created by GlaxoSmithKline, which has strong effects on both Gram-positive and Gram-negative bacteria. It has strong antibacterial activity against Pseudomonas aeruginosa, Enterococcus, Klebsiella, Escherichia coli, Salmonella, Proteus, Shigella, Neisseria gonorrhoeae, Neisseria meningitidis, Staphylococcus aureus, hemolytic Streptococcus, Pneumococcus and Clostridium difficile, especially against Pseudomonas aeruginosa, where ceftazidime is the most effective antibiotic.
  • Ceftazidime injection is a compound preparation of ceftazidime sodium carbonate or ceftazidime arginine, which is obtained by mixing ceftazidime powder with sodium carbonate or arginine powder.
  • the particle size of ceftazidime powder needs to be strictly controlled to improve the applicability of the mixed powder.
  • the application number is 201510104265.0, and the patent name is A ceftazidime powder injection preparation for injection. It discloses a method for preparing ceftazidime, including the following steps: (1) at 5°C to 10°C, weigh the ceftazidime dihydrochloride raw material, add distilled water, stir to dissolve, cool and add alkaline agent to adjust the pH, add activated carbon, filter after decolorization, and wash; (2) at 10°C to 20°C, stir at a speed of 250 to 300 rpm, add acid according to the flow rate table to adjust the pH; (3) filter, wash, and vacuum dry.
  • the technical solution adopted by the present invention is:
  • a method for continuously preparing ceftazidime comprises the following steps:
  • ceftazidime dihydrochloride solution adding ceftazidime dihydrochloride into purified water, stirring to dissolve; adding a decolorizing agent, stirring, filtering, and obtaining a ceftazidime dihydrochloride solution;
  • the crystallization liquid in the crystallizer A exceeds 100 ml
  • the crystallization liquid automatically overflows from the overflow port of the crystallizer A and flows into the crystallizer B.
  • the crystals are grown in the crystallizer B for a period of time, filtered, washed and dried to obtain the ceftazidime product.
  • step S1 the weight ratio of ceftazidime dihydrochloride to purified water is 1:1-2, and the stirring temperature is 0-5°C.
  • a further improvement of the technical solution of the present invention is that the decolorizing agent in step S1 is EDTA, sodium tetrathionate and activated carbon, and the added amounts are 1-5%, 1-5% and 2-6% of the weight of ceftazidime dihydrochloride respectively, and the decolorizing time is 30 minutes.
  • step S2 the weight ratio of sodium hydroxide to purified water is 1:6-7, and the stirring temperature is 0-5°C.
  • a further improvement of the technical solution of the present invention is that the weight ratio of phosphoric acid to purified water in step S3 is 1:3-4.
  • step S4 the flow ratio of the ceftazidime dihydrochloride solution to the sodium hydroxide solution is 1:0.4-0.7, and the residence time in the high-speed centrifugal mixer is 0.5-2s.
  • a further improvement of the technical solution of the present invention is that the temperature of the ceftazidime solution 1 flowing out of the outlet of the high-speed centrifugal mixer is maintained at 0-5°C, and the pH value is maintained at 5.5-6.0.
  • a further improvement of the technical solution of the present invention is that: in the step S5, the weight of the ceftazidime seed crystal suspension added is 10% to 20% of the volume of the crystallizer A, wherein the solid content of the suspension is 5 to 15%, and stirring is performed at 800 rpm for 15 to 30 min.
  • step S5 the stirring speed is reduced to 200-300 rpm, the flow acceleration ratio of ceftazidime solution 1 and phosphoric acid solution is 1:0.20-0.35, and the pH in crystallizer A is 3.5-4.0.
  • a further improvement of the technical solution of the present invention is that: in the S6, the crystallizer B is grown for 30 to 60 minutes, and the pH is kept consistent with that of the crystallizer A, the stirring speed is 100 to 200 rpm, and the temperature is 0 to 5°C.
  • Fig. 1 is a flow chart of the present invention
  • a method for continuously preparing ceftazidime comprises the following steps:
  • ceftazidime dihydrochloride solution adding ceftazidime dihydrochloride to purified water, the weight ratio of ceftazidime dihydrochloride to purified water is 1:1-2, stirring and dissolving at 0-5°C; adding decolorizing agents respectively, stirring for 30 minutes, filtering, and obtaining ceftazidime dihydrochloride solution; wherein the decolorizing agent is a mixture of EDTA, sodium tetrathionate, and activated carbon, and the added amounts are 1-5%, 1-5%, and 2-6% of the weight of ceftazidime dihydrochloride respectively;
  • ceftazidime dihydrochloride solution and sodium hydroxide solution into a high-speed centrifugal mixer at a flow ratio of 1:0.4-0.7, respectively, for rapid mixing to obtain ceftazidime solution 1, which flows out from the outlet of the high-speed centrifugal mixer after staying for 0.5-2 seconds, with the temperature maintained at 0-5°C and the pH value maintained at 5.5-6.0;
  • Embodiment 1 is a diagrammatic representation of Embodiment 1:
  • ceftazidime dihydrochloride solution Take 400g of ceftazidime dihydrochloride, add 650ml of purified water, stir and dissolve at 0-2°C; add EDTA 5g, sodium tetrathionate 5g, activated carbon 10g, stir for 30min, filter, and obtain ceftazidime dihydrochloride solution;
  • ceftazidime dihydrochloride solution and sodium hydroxide solution into a high-speed centrifugal mixer at a flow ratio of 1:0.4-0.7 for rapid mixing to obtain ceftazidime solution 1, which is retained in the high-speed centrifugal mixer for 0.5-1 s and then flows out from the outlet of the high-speed centrifugal mixer.
  • the material temperature at the outlet of the high-speed centrifugal mixer is maintained at 0-5°C and the pH value is maintained at 5.5:
  • the crystallization liquid in the crystallizer A exceeds 100 ml
  • the crystallization liquid automatically overflows from the overflow port of the crystallizer A and flows into the crystallizer B.
  • the crystals are grown in the crystallizer B for 30 minutes, and the pH is maintained at 3.5, the stirring speed is 100-200 rpm, and the temperature is 0-5°C. Then, the crystals are filtered, washed, and dried to obtain the ceftazidime product.
  • Example 2 The process steps of Examples 2 to 4 are the same as those of Example 1, except that the process parameters are changed.
  • the specific process parameters are shown in Table 1.
  • step S4 sodium hydroxide solution is slowly added to the ceftazidime dihydrochloride solution without using a high-speed centrifugal mixer until the pH value is 5.5, the feed liquid is clarified, and ceftazidime solution 1 is obtained after filtration.
  • step S4 sodium hydroxide solution is slowly added to the ceftazidime dihydrochloride solution without using a high-speed centrifugal mixer until the pH value is 5.5, the feed liquid is clarified, and ceftazidime solution 1 is obtained after filtration.
  • step S4 sodium hydroxide solution is slowly added to the ceftazidime dihydrochloride solution without using a high-speed centrifugal mixer until the pH value is 5.5, the feed liquid is clarified, and ceftazidime solution 1 is obtained after filtration.
  • step S4 sodium hydroxide solution is slowly added to the ceftazidime dihydrochloride solution without using a high-speed centrifugal mixer until the pH
  • step S4 sodium hydroxide solution is added to the high-speed stirred ceftazidime dihydrochloride solution at one time in a rapid and quantitative manner without using a high-speed centrifugal mixer, the pH is 5.5 after stirring, the feed liquid is clarified, and ceftazidime solution 1 is obtained after filtering.
  • step S4 sodium hydroxide solution is added to the high-speed stirred ceftazidime dihydrochloride solution at one time in a rapid and quantitative manner without using a high-speed centrifugal mixer, the pH is 5.5 after stirring, the feed liquid is clarified, and ceftazidime solution 1 is obtained after filtering.
  • step S4 sodium hydroxide solution is added to the high-speed stirred ceftazidime dihydrochloride solution at one time in a rapid and quantitative manner without using a high-speed centrifugal mixer, the pH is 5.5 after stirring, the feed liquid is clarified, and ceftazidime solution 1 is obtained after filter
  • Comparative Example 3 The difference between Comparative Example 3 and Example 1 is that: in steps S5 and S6, ceftazidime solution 1 is added to crystallizer A, phosphoric acid solution is added under stirring at 400-600rpm, and the addition of phosphoric acid solution is stopped until the pH is 4.2-4.4, and then 1g of ceftazidime seed suspension is added, and stirred at 200rpm for 30min. The speed is increased to 400-600rpm again, phosphoric acid solution is added under stirring, the pH value is adjusted to 3.5, crystals are grown for 30min, filtered, washed and dried to obtain a ceftazidime product. The remaining steps are the same as in Example 1.
  • Comparative Example 4 was prepared according to the preparation method of ceftazidime in Example 1 of application number 201510104265.0.
  • ceftazidime prepared in Examples 1 to 4 and Comparative Examples 1 to 4 mix with sodium carbonate to prepare a commercially available ceftazidime (sodium carbonate) powder injection of 1.0 g/piece, and test the uniformity of the mixed powder. Take the above samples and mix them with the same sodium carbonate, and use the same mixing method. Take 5 samples of each sample for content and calculate the RSD value. The results are as follows:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种头孢他啶连续制备方法，包括如下步骤：S1、头孢他啶二盐酸盐溶液的制备；S2、氢氧化钠溶液的制备；S3、磷酸溶液的制备；S4、将头孢他啶二盐酸盐溶液与氢氧化钠溶液分别以一定流量加入到高速离心混合器中进行快速混合，然后从高速离心混合器出口流出，得到头孢他啶溶液1；S5、结晶器A中加入头孢他啶晶种与水的混悬液，同时连续匀速地加入头孢他啶溶液1和磷酸溶液；S6、当结晶器A内结晶液体积超过100ml，结晶液自动从结晶器A中溢出并流入结晶器B，在结晶器B中养晶一段时间，过滤，洗涤干燥，得到头孢他啶产品，本发明能够显著降低杂质的含量，尤其是RRT＝0.82的杂质含量，提高纯度，且粉体粒径均匀。

Description

一种头孢他啶连续制备方法 技术领域
本发明涉及一种头孢他啶连续制备方法，属于医药技术领域。
背景技术
头孢他啶是由葛兰素史克公司创制的第三代头孢菌素类抗生素，对革兰阳性或阴性菌均具有较强作用。对绿脓杆菌、肠球菌、克雷白杆菌、大肠杆菌、沙门菌、变形杆菌、志贺菌、淋病奈瑟菌、脑膜炎奈瑟菌、金葡菌、溶血性链球菌、肺炎球菌及产气杆菌等具有强的抗菌活性，特别是对于绿脓杆菌，头孢他啶是作用最强的抗生素。
头孢他啶注射剂为头孢他啶碳酸钠或头孢他啶精氨酸复方制剂，是将头孢他啶粉体与碳酸钠或精氨酸粉体进行混合得到的，为了提高混合均匀度、混合效率以及稳定性，在制备头孢他啶粉体时，需要对头孢他啶粉体的粒径进行严格控制，提高混粉适用性。
在制备头孢他啶粉体时，除了控制头孢他啶粉体的粒径外，还要控制杂质的含量，尤其是RRT＝0.82的杂质，不易去除而带入产品中，影响产品的质量。
申请号为201510104265.0，专利名称为一种注射用头孢他啶粉针制剂公开了一种头孢他啶的制备方法，包括以下过程：(1)在5℃～10℃下，称取头孢他啶二盐酸盐原料，加入蒸馏水，搅拌溶解，降温滴加碱性剂调节pH，加入活性炭，脱色后过滤，洗涤；(2)在10℃～20℃下，搅拌速度为250～300转/min下，按流加速率表加入酸调节pH；(3)抽滤，洗涤，真空干燥。
但是，上述方法得到的头孢他啶杂质含量较高，尤其是RRT＝0.82的杂质含量也比较高，并且得到的粉体粒径不均匀，不利于后续的混粉。
并且，在现有的认知中，头孢他啶二盐酸盐溶液与碱性剂混合时，为了防止局部过碱造成降解，通常会采用滴加的方式，并控制滴加速度。
发明内容
本发明为解决上述技术问题，提供一种头孢他啶连续制备方法，能够连续生产，并且能够显著降低杂质的含量，尤其是RRT＝0.82的杂质含量，提高纯度，且粉体粒径均匀。
为解决上述技术问题，本发明所采用的技术方案是：
一种头孢他啶连续制备方法，包括如下步骤：
S1、头孢他啶二盐酸盐溶液的制备：将头孢他啶二盐酸盐加入纯化水中，搅拌溶解；加入脱色剂搅拌，过滤，得到头孢他啶二盐酸盐溶液；
S2、氢氧化钠溶液的制备：氢氧化钠加入纯化水中，搅拌溶解；
S3、磷酸溶液的制备：磷酸加入纯化水中，搅拌均匀；
S4、将头孢他啶二盐酸盐溶液与氢氧化钠溶液分别以一定流量加入到高速离心混合器中进行快速混合，然后从高速离心混合器出口流出，得到头孢他啶溶液1；
S5、结晶器A中加入头孢他啶晶种和水的混悬液，快速搅拌一段时间，然后降低搅拌速度，同时连续匀速地加入头孢他啶溶液1和磷酸溶液；
S6、当结晶器A内结晶液体积超过100ml，结晶液自动从结晶器A的溢流口溢出并流入结晶器B，在结晶器B中养晶一段时间，过滤，洗涤干燥，得到头孢他啶产品。
本发明技术方案的进一步改进在于：所述步骤S1中头孢他啶二盐酸盐与纯化水的重量比为1∶1～2，搅拌温度为0～5℃。
本发明技术方案的进一步改进在于：所述步骤S1中的脱色剂为EDTA、连四硫酸钠和活性炭，加入量分别为头孢他啶二盐酸盐重量的1～5％、1～5％、2～6％，脱色时间为30min。
本发明技术方案的进一步改进在于：所述步骤S2中氢氧化钠与纯化水的重量比为1∶6～7，搅拌温度为0-5℃。
本发明技术方案的进一步改进在于：所述步骤S3中磷酸与纯化水的重量比为1∶3～4。
本发明技术方案的进一步改进在于：所述步骤S4中头孢他啶二盐酸盐溶液与氢氧化钠溶液的流量比为1∶0.4～0.7，在高速离心混合器中停留时间为0.5～2s。
本发明技术方案的进一步改进在于：所述高速离心混合器出口流出的头孢他啶溶液1的温度维持在0～5℃，pH值维持在5.5～6.0。
本发明技术方案的进一步改进在于：所述步骤S5中头孢他啶晶种混悬液的加入重量为结晶器A容积的10％～20％，其中混悬液中的固含量为5～15％，800rpm搅拌15～30min。
本发明技术方案的进一步改进在于：所述步骤S5中搅拌速度降低到200-300rpm，头孢他啶溶液1和磷酸溶液的流加速度比为1∶0.20～0.35，结晶器A内的pH为3.5～4.0。
本发明技术方案的进一步改进在于：所述S6中结晶器B养晶30～60min，并与结晶器A的pH保持一致，搅拌速度100～200rpm，温度0～5℃。
由于采用了上述技术方案，本发明取得的技术进步是：
1)产品质量提升，其中RRT＝0.82的单杂和总杂显著减少，含量提升；
2)粒度均匀，密度适中，易于制剂使用；
3)降解减少，收率明显提高；
4)提高了生产效率，降低了批间差异。
附图说明
图1是本发明的流程图；
具体实施方式
下面结合实施例对本发明做进一步详细说明：
一种头孢他啶连续制备方法，包括如下步骤：
S1、头孢他啶二盐酸盐溶液的制备：将头孢他啶二盐酸盐加入纯化水中，头孢他啶二盐酸盐：纯化水的重量比为1∶1～2，0～5℃搅拌溶解；分别加入脱色剂搅拌30min，过滤，得到头孢他啶二盐酸盐溶液；其中，脱色剂为EDTA、连四硫酸钠、活性炭的混合物，加入量分别为头孢他啶二盐酸盐重量的1～5％、1～5％、2～6％；
S2、氢氧化钠溶液的制备：氢氧化钠加入纯化水中，氢氧化钠∶纯化水为1∶6～7(重 量比)，0-5℃搅拌溶解；
S3、磷酸溶液的制备：磷酸加入纯化水中，磷酸∶纯化水为1∶3～4(重量比)，搅拌均匀；
S4、将头孢他啶二盐酸盐溶液与氢氧化钠溶液分别以1∶0.4～0.7的流量比加入到高速离心混合器中进行快速混合，得到头孢他啶溶液1，停留0.5～2s后从高速离心混合器出口流出，温度维持在0～5℃，pH值维持在5.5～6.0；
S5、结晶器A中加入头孢他啶晶种混悬液和水，头孢他啶晶种混悬液的加入重量为结晶器A容积的10％～20％，其中混悬液中的固含量为5～15％，800rpm搅拌15～30min，然后降低搅拌速度到200-300rpm，同时连续匀速地加入头孢他啶溶液1和磷酸溶液，头孢他啶溶液1和磷酸溶液的流加速度比为1∶0.20～0.35，保持结晶器A内pH为3.5～4.0；
S6、当结晶器A内结晶液体积超过100ml，结晶液自动从结晶器A的溢流口溢出并流入结晶器B，在结晶器B中养晶30min，并与结晶器A的pH保持一致，搅拌速度100～200rpm，温度0～5℃，过滤，洗涤干燥，得到头孢他啶产品。
实施例1：
S1、头孢他啶二盐酸盐溶液的制备：取400g头孢他啶二盐酸盐，加入650ml纯化水，0～2℃搅拌溶解；加入EDTA 5g、连四硫酸钠5g、活性炭10g，搅拌30min，过滤，得到头孢他啶二盐酸盐溶液；
S2、氢氧化钠溶液的制备：氢氧化钠80g，加入500ml纯化水，搅拌溶解，0-2℃备用；
S3、磷酸溶液的制备：150g磷酸(浓度为90～95％)，加入600ml纯化水，搅拌均匀备用；
S4、将头孢他啶二盐酸盐溶液与氢氧化钠溶液分别以1∶0.4～0.7的流量比加入到高速离心混合器中进行快速混合，得到头孢他啶溶液1，在高速离心混合器保留时间0.5～1s，然后从高速离心混合器出口流出，高速离心混合器出口物料温度维持0～5℃，pH值维持5.5：
S5、结晶器A中加入1g头孢他啶晶种混悬液25ml水，800rpm搅拌30min，降低搅拌速度到200-300rpm，同时匀速连续加入头孢他啶溶液1和磷酸溶液，加入的速度比为1∶0.20～0.35，保持结晶器A内pH为3.5；
S6、当结晶器A内结晶液体积超过100ml，结晶液自动从结晶器A的溢流口溢出并流入结晶器B，在结晶器B中养晶30min，并保持pH3.5，搅拌速度100～200rpm，温度0～5℃，然后过滤洗涤干燥，得到头孢他啶产品。
实施例2～4
实施例2～4与实施例1的工艺步骤相同，只是在工艺参数上有改变，具体的工艺参数如表1。
表1实施例1～4的工艺参数表
对比例1：
对比例1与实施例1的区别在于：步骤S4中向头孢他啶二盐酸盐溶液中缓慢加入氢氧化钠溶液，不采用高速离心混合器，直到PH值5.5，料液澄清，过滤后得到头孢他啶溶液1。其余步骤与实施例1相同。
对比例2：
对比例1与实施例1的区别在于：步骤S4中向高速搅拌的头孢他啶二盐酸盐溶液中一次性快速定量加入氢氧化钠溶液，不采用高速离心混合器，搅拌均匀后PH5.5，料液澄清，过滤后得到头孢他啶溶液1。其余步骤与实施例1相同。
对比例3：
对比例3与实施例1的区别在于：步骤S5和S6中将头孢他啶溶液1加入结晶器A中，400～600rpm搅拌下加入磷酸溶液，直至pH为4.2～4.4停止加磷酸溶液，然后加入1g头孢他啶晶种混悬液，搅拌200rpm30min。再次提高转速到400～600rpm搅拌下加入磷酸溶液，调节PH值到3.5，养晶30min，过滤洗涤干燥，得到头孢他啶产品。其余步骤与实施例1相同。
对比例4：
根据申请号为201510104265.0中实施例1的头孢他啶的制备方法进行制备得到对比例4。
实验结果检测：
取实施例1～4、对比例1～4制备的头孢他啶，按照EP药典方法检测总杂、RRT＝ 0.82的杂质、含量，并按照下式计算摩尔收率：((头孢他啶的质量/头孢他啶分子量)/(头孢他啶二盐酸盐的质量/头孢他啶二盐酸盐分子量)×100％，结果如表2所示：
表2实验结果检测表
取实施例1～4、对照例1～4制备的头孢他啶，与碳酸钠混合制成市售1.0g/支规格的头孢他啶(碳酸钠)粉针剂，检测其混粉均匀性。取以上样品与同一碳酸钠混合，相同的混匀方式，每个样品取样5个进行含量并计算RSD值，结果如下：

Claims (10)

  1. 一种头孢他啶连续制备方法，其特征在于：包括如下步骤：
    S1、头孢他啶二盐酸盐溶液的制备：将头孢他啶二盐酸盐加入纯化水中，搅拌溶解；加入脱色剂搅拌，过滤，得到头孢他啶二盐酸盐溶液；
    S2、氢氧化钠溶液的制备：氢氧化钠加入纯化水中，搅拌溶解；
    S3、磷酸溶液的制备：磷酸加入纯化水中，搅拌均匀；
    S4、将头孢他啶二盐酸盐溶液与氢氧化钠溶液分别以一定流量加入到高速离心混合器中进行快速混合，然后从高速离心混合器出口流出，得到头孢他啶溶液1；
    S5、结晶器A中加入头孢他啶晶种和水的混悬液，快速搅拌一段时间，然后降低搅拌速度，同时连续匀速地加入头孢他啶溶液1和磷酸溶液；
    S6、当结晶器A内结晶液体积超过100ml，结晶液自动从结晶器A的溢流口溢出并流入结晶器B，在结晶器B中养晶一段时间，过滤，洗涤干燥，得到头孢他啶产品。
  2. 根据权利要求1所述的一种头孢他啶连续制备方法，其特征在于：所述步骤S1中头孢他啶二盐酸盐与纯化水的重量比为1∶1～2，搅拌温度为0～5℃。
  3. 根据权利要求1所述的一种头孢他啶连续制备方法，其特征在于：所述步骤S1中的脱色剂为EDTA、连四硫酸钠和活性炭，加入量分别为头孢他啶二盐酸盐重量的1～5％、1～5％、2～6％，脱色时间为30min。
  4. 根据权利要求1所述的一种头孢他啶连续制备方法，其特征在于：所述步骤S2中氢氧化钠与纯化水的重量比为1∶6～7，搅拌温度为0-5℃。
  5. 根据权利要求1所述的一种头孢他啶连续制备方法，其特征在于：所述步骤S3中磷酸与纯化水的重量比为1∶3～4。
  6. 根据权利要求1所述的一种头孢他啶连续制备方法，其特征在于：所述步骤S4中头孢他啶二盐酸盐溶液与氢氧化钠溶液的流量比为1∶0.4～0.7，在高速离心混合器中停留时间为0.5～2s。
  7. 根据权利要求1所述的一种头孢他啶连续制备方法，其特征在于：所述高速离心混合器出口流出的头孢他啶溶液1的温度维持在0～5℃，pH值维持在5.5～6.0。
  8. 根据权利要求1所述的一种头孢他啶连续制备方法，其特征在于：所述步骤S5中头孢他啶晶种混悬液的加入重量为结晶器A容积的10％～20％，其中混悬液中的固含量为5～15％，800rpm搅拌15～30min。
  9. 根据权利要求1所述的一种头孢他啶连续制备方法，其特征在于：所述步骤S5中搅拌速度降低到200-300rpm，头孢他啶溶液1和磷酸溶液的流加速度比为1∶0.20～0.35，结晶器A内的pH为3.5～4.0。
  10. 根据权利要求1所述的一种头孢他啶连续制备方法，其特征在于：所述S6中结晶器B养晶30～60min，并与结晶器A的pH保持一致，搅拌速度100～200rpm，温度0～5℃。
PCT/CN2023/089405 2022-10-31 2023-04-20 一种头孢他啶连续制备方法 WO2024093156A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211349081.7 2022-10-31
CN202211349081.7A CN115724855A (zh) 2022-10-31 2022-10-31 一种头孢他啶连续制备方法

Publications (1)

Publication Number Publication Date
WO2024093156A1 true WO2024093156A1 (zh) 2024-05-10

Family

ID=85294212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/089405 WO2024093156A1 (zh) 2022-10-31 2023-04-20 一种头孢他啶连续制备方法

Country Status (2)

Country Link
CN (1) CN115724855A (zh)
WO (1) WO2024093156A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115724855A (zh) * 2022-10-31 2023-03-03 华北制药河北华民药业有限责任公司 一种头孢他啶连续制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391289A (zh) * 2011-12-03 2012-03-28 齐鲁安替制药有限公司 头孢他啶中间体及头孢他啶的合成方法
CN104666249A (zh) * 2015-03-10 2015-06-03 华北制药河北华民药业有限责任公司 一种注射用头孢他啶粉针制剂
CN107722040A (zh) * 2017-10-10 2018-02-23 南京志坤环保科技有限公司 一种回收利用头孢他啶母液的膜分离方法及装置
CN109824698A (zh) * 2019-01-23 2019-05-31 华北制药河北华民药业有限责任公司 一种头孢他啶的制备方法
WO2021212535A1 (zh) * 2020-04-25 2021-10-28 江苏天士力帝益药业有限公司 一种盐酸苯海索精制方法
CN115724855A (zh) * 2022-10-31 2023-03-03 华北制药河北华民药业有限责任公司 一种头孢他啶连续制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101607966A (zh) * 2008-06-19 2009-12-23 上海新先锋药业有限公司 头孢他啶五水合物的制备方法
CN103044457B (zh) * 2012-10-22 2014-07-02 深圳华润九新药业有限公司 头孢他啶纯化方法
CN104876949A (zh) * 2015-05-28 2015-09-02 浙江长典医药有限公司 一种小儿用头孢他啶化合物实体及其制剂
CN108558908B (zh) * 2018-06-06 2019-11-29 华北制药河北华民药业有限责任公司 一种头孢他啶母液的除盐方法及头孢他啶的制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391289A (zh) * 2011-12-03 2012-03-28 齐鲁安替制药有限公司 头孢他啶中间体及头孢他啶的合成方法
CN104666249A (zh) * 2015-03-10 2015-06-03 华北制药河北华民药业有限责任公司 一种注射用头孢他啶粉针制剂
CN107722040A (zh) * 2017-10-10 2018-02-23 南京志坤环保科技有限公司 一种回收利用头孢他啶母液的膜分离方法及装置
CN109824698A (zh) * 2019-01-23 2019-05-31 华北制药河北华民药业有限责任公司 一种头孢他啶的制备方法
WO2021212535A1 (zh) * 2020-04-25 2021-10-28 江苏天士力帝益药业有限公司 一种盐酸苯海索精制方法
CN115724855A (zh) * 2022-10-31 2023-03-03 华北制药河北华民药业有限责任公司 一种头孢他啶连续制备方法

Also Published As

Publication number Publication date
CN115724855A (zh) 2023-03-03

Similar Documents

Publication Publication Date Title
JP3854765B2 (ja) 長鎖ジカルボン酸の精製方法
CN102010426B (zh) 一种制备头孢唑肟钠的方法
WO2024093156A1 (zh) 一种头孢他啶连续制备方法
CN100506210C (zh) 一种头孢替唑钠粉针及其合成方法
CN104370941A (zh) 注射用头孢曲松钠的制备方法
WO2023202567A1 (zh) 一种头孢噻肟钠的精制方法
CN114149374B (zh) 一种高分散氯氮平原料药晶体颗粒的制备方法
CN106987608B (zh) 一种葡萄糖酸钙的动态结晶法
EP4424660A1 (en) Preparation system and method for xylitol crystal
CN101906109B (zh) 一种头孢呋辛钠的制备方法
CN107188798A (zh) 一种可控制粒度的枸橼酸钠的精制工艺及实现装置
CN105753728B (zh) 一种药用级l‑缬氨酸的溶析结晶方法
CN102079749B (zh) 利福平原料药≤0.3g/ml及≥0.8g/ml密度规格的生产方法
CN106478668A (zh) 一种头孢呋辛酸结晶的制备工艺
JP2007238596A (ja) アミノ酸の二塩酸塩の生成のための直接的なプロセス
CN105622634A (zh) 一种头孢唑肟酸的生产方法
CN111518119B (zh) 一种阿莫西林连续结晶工艺
CN104650115A (zh) 头孢哌酮钠及其复方特种超细粉体制剂与制备方法
CN108690049A (zh) 从酶法制备阿莫西林的反应产物中分离阿莫西林的方法
CN112679524B (zh) 一种头孢曲松钠的制备方法
CN109734724B (zh) 一种哌拉西林酸的结晶方法
CN114149477A (zh) 一种高纯度维生素b12晶体的结晶方法及其产品
CN103755726A (zh) 一种头孢洛宁的精制提纯方法
CN109400491B (zh) 一种左旋对羟基苯甘氨酸甲酯的结晶制备方法
WO2013010297A1 (zh) 纯化头孢唑肟钠的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23884099

Country of ref document: EP

Kind code of ref document: A1